Cohance Lifesciences Ltd logo

Cohance Lifesciences Ltd

COHANCE NSE

Hyderabad based CDMO company that offers services to leading global pharmaceutical and fine chemical majors in their NCE development endeavours. From process research & development to late-stage clinical and commercial manufacturing we are committed to provide customers with products fulfilling customer needs and expectations.[1]

AI Verdict: SELL Confidence: 7%

Cohance Lifesciences trades at an expensive PE of 103.6x with declining profitability (compounded profit CAGR of -21% over 3 years) and deteriorating working capital efficiency. Despite strong TTM sales growth of 89%, the stock has lost 59% in the past year, reflecting eroding investor confidence.

Key Fundamentals

SmallcapPharmaceuticalsHealthcare
Market Cap
₹17,382 Cr
Volatility
Moderate
P/E Ratio
97.67
EBITDA
₹398 Cr
Return on Equity
14.64%
Debt to Equity
0.09
Book Value
₹102.24
EPS
₹9.45
52W High
₹1,121.15
52W Low
₹266.7

Technical Indicators

Key Insights

Weaknesses

5
  • Stock is trading at 4.52 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of 10.7% over last 3 years.
  • Debtor days have increased from 80.9 to 110 days.
  • Working capital days have increased from 122 days to 175 days

Growth Rate

Revenue Growth
80.60% ↗
Net Income Growth
-51.98% ↗
Cash Flow Change
-19.62% ↘
ROE
-1.78% ↗
ROCE
-30.56% ↗
EBITDA Margin (Avg.)
-50.01% ↘

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 1d ago
SELL
Risk high

Cohance Lifesciences trades at an expensive PE of 103.6x with declining profitability (compounded profit CAGR of -21% over 3 years) and deteriorating working capital efficiency. Despite strong TTM sales growth of 89%, the stock has lost 59% in the past year, reflecting eroding investor confidence.

Bull Case 7
  • TTM revenue growth of 89% indicates a significant acceleration in top-line momentum
  • 3-year compounded sales CAGR of 19% shows consistent revenue expansion over medium term
  • 5-year compounded sales CAGR of 18% demonstrates sustained business scalability
  • Dividend yield of 1.48% provides some income cushion for investors in a growth stock
  • Market cap of Rs 16,772 Cr provides reasonable liquidity and institutional interest
  • 3-year average ROE of 11% shows the business is generating returns above cost of debt
  • 37.5% of analysts have a buy rating, suggesting some see value at current levels
Bear Case 8
  • PE ratio of 103.6x is extremely expensive relative to sector peers and declining earnings trajectory
  • Stock price CAGR of -59% over 1 year reflects severe destruction of shareholder value
  • Compounded profit CAGR of -21% over 3 years signals structural earnings deterioration
  • Debtor days have increased from 80.9 to 110 days, indicating worsening collection efficiency
  • Working capital days have ballooned from 122 to 175 days, straining cash flows
  • ROE has declined from 5-year average of 16% to just 7% last year, showing deteriorating capital efficiency
  • 50% of analysts rate the stock a Sell versus only 37.5% Buy, reflecting bearish consensus
  • Trading at 3.96x book value is expensive given low ROE of 7% in the last year

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 14h ago
Headwinds 2
  • CFO resigns effective Sep 13 Jun 17

    CFO Himanshu Agarwal resigned effective Sep 13, 2026 to pursue external opportunities. Leadership gap at a key finance role creates near-term uncertainty.

  • 54.36% promoter stake pledged Jun 19

    Promoters Berhyanda Limited and Jusmiral Holdings pledged 207.97 million shares (54.36% stake) to secure a USD 285M term loan from a consortium of lenders for debt refinancing. High promoter pledge levels increase risk in a downturn.

Positives 2
  • Umang Vohra appointed Chairman & CEO Jun 14

    Shareholders approved Umang Vohra as Chairman and Group CEO along with ESOP 2026 plan. Strong leadership appointment signals strategic direction for growth.

  • Active investor engagement planned Jun 2

    Management scheduled attendance at Citi (Jun 5) and ICICI Securities (Jun 9) conferences in Mumbai, signaling proactive outreach to institutional investors.

Neutral 1
  • No new share encumbrances declared Jun 23

    Promoter Berhyanda Limited confirmed no new encumbrances on shares in FY 2025-26 beyond prior disclosures. Pledge levels remain unchanged from earlier filings.

TL;DR: Cohance Lifesciences is undergoing leadership transition with a credible new Chairman & Group CEO in Umang Vohra, but faces near-term risks from a CFO departure and a heavily pledged promoter stake (54.36% for USD 285M refinancing). The debt refinancing suggests legacy leverage is being managed but not reduced. Investors should monitor the CFO replacement timeline and whether the high promoter pledge ratio stabilizes or triggers margin calls in volatile markets.

Quarterly Results

  Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales
369
348
231
220
253
488
604
676
840
549
556
545
619
Expenses
198
181
133
154
180
363
398
439
611
437
435
449
520
Operating Profit
172
167
97.96
66.08
73.35
125
205
237
229
112
121
95.35
98.68
OPM %
46.53%
48.04%
42.4%
30.06%
29%
25.63%
34.01%
35.1%
27.27%
20.39%
21.77%
17.51%
15.94%
Other Income
11.4
10.67
19.84
14.34
17.05
19.41
16.19
21.56
-3.73
6.07
15.6
1.3
-18.35
Interest
5.03
1.15
0.5
2.16
2.3
10.2
9.61
10.8
10.45
10.18
8.76
9.11
9.19
Depreciation
12.02
12.54
11.89
12.79
17.25
31.28
37.79
43.56
54.17
45.14
44.02
46.94
51.23
PBT
166
164
105
65.47
70.85
103
174
205
161
62.76
83.77
40.6
19.91
Tax %
25.41%
26.44%
24.51%
28.59%
24.67%
26.85%
20.62%
24.97%
27.18%
26.07%
20.75%
28.52%
58.26%
Net Profit
124
121
79.56
46.75
53.37
75.37
138
153
117
46.4
66.39
29.02
8.31
EPS in Rs
4.87
4.74
3.13
1.84
2.1
2.96
5.44
6.01
4.73
1.28
1.94
0.96
0.51
Figures in ₹ Crores

Profit & Loss

  Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales
378
834
1,010
1,320
1,340
1,051
1,198
2,269
Expenses
206
449
567
738
766
645
822
1,842
Operating Profit
172
385
443
582
574
406
375
427
OPM %
45%
46%
44%
44%
43%
39%
31%
19%
Other Income
1
66
68
133
46
62
58
5
Interest
3
23
12
9
13
7
12
37
Depreciation
12
24
32
39
48
55
77
187
PBT
158
405
468
668
560
406
344
207
Tax %
31%
22%
23%
32%
27%
26%
23%
27%
Net Profit
109
317
362
454
411
300
265
150
EPS in Rs
—
12.45
14.23
17.83
16.16
11.8
10.52
4.68
Div. Payout %
0%
20%
14%
28%
37%
0%
0%
0%
Figures in ₹ Crores

Balance Sheet

  Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
0
13
25
25
25
25
25
38
Reserves
578
832
1,155
1,502
1,710
2,025
1,671
3,873
Borrowings
83
186
143
97
70
65
279
400
Other Liabilities
123
142
151
205
160
138
1,056
1,418
Total Liabilities
783
1,173
1,474
1,830
1,966
2,254
3,031
5,730
Fixed Assets
271
357
441
534
663
670
1,713
3,373
CWIP
111
102
96
30
165
179
256
173
Investments
7
338
542
598
536
904
337
529
Other Assets
394
376
395
667
601
501
725
1,655
Total Assets
783
1,173
1,474
1,830
1,966
2,254
3,031
5,730
Figures in ₹ Crores

Cash Flow

  Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
50
407
383
330
457
358
288
368
Investing
-65
-413
-311
-136
-195
-362
-253
-255
Financing
26
7
-76
-156
-242
-14
3
-165
Net Cash Flow
11
1
-5
37
20
-18
38
-51
Free Cash Flow
-6
304
272
255
171
307
132
169
CFO/OP
49
128
111
88
105
115
99
102
Figures in ₹ Crores

Ratios

  Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
142
51
37
65
30
46
87
110
Inventory Days
556
278
243
259
279
268
199
310
Days Payable
190
113
100
97
63
49
96
157
Cash Conversion Cycle
509
217
180
228
247
265
190
263
Working Capital Days
205
64
56
108
99
115
74
175
ROCE %
—
50%
40%
41%
32%
19%
15%
8%

Shareholding Pattern

As of Mar 2026
Promoters 57.49%
DIIs 21.79%
Others 8.08%
Public 7.04%
FIIs 5.59%
Government 0.01%
Total 100.00%
  Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025May 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters
60.00%
60.00%
60.00%
60.00%
60.00%
60.00%
60.00%
60.00%
60.00%
60.00%
60.00%
60.00%
50.10%
50.10%
50.10%
50.10%
50.10%
66.41%
66.41%
57.49%
57.49%
57.49%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
10.01%
10.14%
9.54%
9.80%
10.70%
10.84%
11.05%
7.38%
7.23%
6.51%
6.02%
5.59%
DIIs
4.30%
4.47%
4.94%
5.24%
5.91%
6.32%
10.52%
11.35%
11.43%
9.23%
14.14%
15.94%
17.24%
17.42%
16.94%
16.68%
16.60%
11.02%
11.40%
20.82%
21.57%
21.79%
Government
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
Public
20.87%
19.86%
19.21%
18.38%
17.07%
16.86%
14.69%
14.01%
12.76%
12.80%
11.76%
10.87%
10.51%
10.08%
9.75%
9.81%
9.68%
6.63%
6.40%
6.42%
6.76%
7.04%
Others
14.84%
15.68%
15.86%
16.38%
17.02%
16.82%
14.78%
14.64%
15.81%
17.97%
4.08%
3.04%
12.59%
12.59%
12.50%
12.56%
12.55%
8.55%
8.55%
8.75%
8.16%
8.08%
No. of Shareholders
75,207
92,534
96,532
86,447
85,725
86,088
82,577
79,412
72,885
72,167
73,715
70,052
68,932
65,777
69,337
84,210
86,325
88,658
80,910
75,284
81,877
85,230

Documents

Frequently Asked Questions about Cohance Lifesciences Ltd

What does Cohance Lifesciences Ltd do?
Hyderabad based CDMO company that offers services to leading global pharmaceutical and fine chemical majors in their NCE development endeavours. From process research & development to late-stage clinical and commercial manufacturing we are committed to provide customers with products fulfilling c...
Where is Cohance Lifesciences Ltd (COHANCE) listed?
Cohance Lifesciences Ltd is listed on the Indian stock exchanges. It is listed on NSE: COHANCE and BSE: 543064. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Cohance Lifesciences Ltd belong to?
Cohance Lifesciences Ltd operates in the Healthcare sector within the Pharmaceuticals & Biotechnology industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Cohance Lifesciences Ltd?
Cohance Lifesciences Ltd has a market capitalisation of approximately ₹17381.94 Cr. Based on this, it is classified as a Mid Cap stock.
What is the PE ratio of Cohance Lifesciences Ltd?
The Price-to-Earnings (PE) ratio of Cohance Lifesciences Ltd is 97.67. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Cohance Lifesciences Ltd?
Over the past 52 weeks, Cohance Lifesciences Ltd has traded between a low of ₹266.7 and a high of ₹1,121.15. This range helps investors understand the stock's price volatility and recent trading levels.
Does Cohance Lifesciences Ltd pay dividends?
Yes, Cohance Lifesciences Ltd has a dividend yield of 1.30%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Cohance Lifesciences Ltd?
Cohance Lifesciences Ltd has a Return on Equity (ROE) of 14.64%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Cohance Lifesciences Ltd on Tapetide?
On Tapetide, you can view Cohance Lifesciences Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Hyderabad based CDMO company that offers services to leading global pharmaceutical and fine chemical majors in their NCE development endeavours. From process research & development to late-stage clinical and commercial manufacturing we are committed to provide customers with products fulfilling customer needs and expectations.[1]

Website cohance.com
CEO Mr. Vivek Sharma CPA
Employees 1,212
Listed 2020-03-09
Face Value ₹ 1
Issued Size 38,25,67,140

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List